A brand new anti-microbial product has been launched by Indian drug company Sun Pharma and has attracted strong praise from health experts, who have expressed satisfaction that the product is effective against the infections that plague some of the world’s most important cities.
The company has been making its first foray into the world of public health, having launched its first product, the ‘Kilani Anti-Inflammatory Skin Oil’, last year.
The company, which has a portfolio of over 40 drugs and is currently in talks with pharmaceutical giant GlaxoSmithKline, says it is also exploring the potential for a drug to treat and prevent a wide range of illnesses, including colds, flu and bronchitis.
The product, dubbed ‘Kilsani’, comes in three varieties – the standard, ‘superior’ and ‘supercharged’ varieties.
The supercharged version is available in a range of sizes ranging from two to five ml, with the ‘super-charged’ variety available in the range of six to 12 ml.
Sun Pharma has been launching new anti, anti-inflammatory and anti-viral drugs in recent years.
Last year, it launched ‘Kilo’ a drug that is designed to reduce the risk of lung cancer.
Sun Pharma also launched ‘Purity’ in 2017, a new anti bacterial product that is meant to treat the diseases that plague most cities, including Mumbai, Chennai, Delhi, Pune, Bangalore, Chennai and Hyderabad.
Sun’s new anti anti-inflammatories, called ‘Kilelani’ and its ‘superb’ anti-fungal drug, ‘Kila’, were the mainstays of a clinical trial carried out by the Indian Institute of Medical Sciences (IIMS) in Bengaluru in which it was found that ‘KILANI’ was effective in the treatment of pulmonary tuberculosis and bronchiectasis, which is also associated with respiratory infections.
Sun is also currently in the process of exploring the possibility of producing a drug for asthma.
Sun says that the anti-inflammatory drug is designed for use in the prevention of respiratory infections and is effective in reducing the risk to the lungs and the circulation of airways.
It is available at a range in the standard and supercharged varieties, with both the varieties available in 6 ml and 12 ml sizes.
“This product has proven to be very effective against respiratory infections including coughs, wheezes and rhinitis,” Sun Pharma said in a statement.
Sun said the new anti infections also have a wide array of applications, including in the management of respiratory conditions and in the development of new products, which include anti-cholera and anti pneumonia vaccines.
The new anti drugs are currently undergoing clinical trials and are being evaluated by various government agencies in different countries, including India.
The drug is expected to be available in India by March 2018.